Multimodal Single-Cell Transcriptomic and Proteomic Correlatives of Patients Outcomes Following Anti-BCMA Cellular Therapy with Ciltacabtagene Autoleucel (Cilta-cel) in Relapsed Multiple Myeloma

被引：1

作者：

dos Santos, Junia Vieira ^{[1
]}

Melnekoff, David ^{[1
]}

Aleman, Adolfo ^{[2
]}

Bhalla, Sherry ^{[3
]}

Mouhieddine, Tarek H. ^{[2
]}

Van Oekelen, Oliver ^{[2
]}

Rajeeve, Sridevi ^{[4
]}

Upadhyaya, Bhaskar ^{[2
]}

Ghodke-Puranik, Yogita ^{[1
]}

Leshchenko, Violetta ^{[5
]}

Rahman, Adeeb ^{[6
]}

Afik, Shaked ^{[6
]}

Lewinsky, Hadas ^{[6
]}

Thibaud, Santiago ^{[2
]}

Cho, Hearn Jay ^{[2
]}

Richter, Joshua ^{[2
]}

Rodriguez, Cesar ^{[2
]}

Sanchez, Larysa ^{[2
]}

Rossi, Adriana C. ^{[2
]}

Richard, Shambavi ^{[2
]}

Chari, Ajai ^{[7
]}

Jagannath, Sundar ^{[1
]}

Parekh, Samir ^{[2
]}

Lagana, Alessandro ^{[5
]}

机构：

[1] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA

[2] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Med Hematol & Med Oncol, New York, NY 10029 USA

[3] Mt Sinai Hosp, New York, NY 10029 USA

[4] Mt Sinai, New York, NY USA

[5] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[6] ImmunAI, New York, NY USA

[7] Mt Sinai Sch Med, New York, NY USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-186395

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[1] Outcomes of Outpatient Administration of Ciltacabtagene Autoleucel (Cilta-cel) in Relapsed Refractory Multiple Myeloma (RRMM)
Gregory, Tara
De Braganca, Kevin C.
Alegria, Victoria
Perciavalle, Matthew
Ranjan, Sandip
Mothe, Raj Kumar
Bixby, Todd
Qureshi, Zaina P.
BLOOD, 2024, 144 : 7591 - 7592
[2] Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma
Costa, Luciano J.
Lin, Yi
Cornell, R. Frank
Martin, Thomas
Chhabra, Saurabh
Usmani, Saad Z.
Jagannath, Sundar
Callander, Natalie S.
Berdeja, Jesus G.
Kang, Yubin
Vij, Ravi
Godby, Kelly N.
Malek, Ehsan
Neppalli, Amarendra
Liedtke, Michaela
Fiala, Mark
Tian, Hong
Valluri, Satish
Marino, Jennifer
Jackson, Carolyn C.
Banerjee, Arnob
Kansagra, Ankit
Schecter, Jordan M.
Kumar, Shaji
Hari, Parameswaran
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (05): : 326 - 335
[3] Efficacy and Safety of Cilta-Cel in Patients with Progressive Multiple Myeloma after Exposure to Non-Cellular Anti-BCMA Immunotherapy
Cohen, Adam D.
Mateos, Maria-Victoria
Cohen, Yael C.
Rodriguez Otero, Paula
Paiva, Bruno
Van de Donk, Niels W. C. J.
Martin, Thomas
Suvannasankha, Attaya
Corsale, Christina
Schecter, Jordan M.
De Braganca, Kevin C.
Jackson, Carolyn C.
Varsos, Helen
Deraedt, William
Roccia, Tito
Mistry, Pankaj
Xu, Xiaoying
Li, Katherine
Zudaire, Enrique
Akram, Muhammad
Pacaud, Lida
Avivi, Irit
San-Miguel, Jesus
BLOOD, 2022, 140 : 4646 - 4648
[4] CILTA-CEL EFFICACY AND SAFETY IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER NONCELLULAR ANTI-BCMA IMMUNOTHERAPY
Mateos, Maria-Victoria
Cohen, Adam
Cohen, Yael
Rodriguez-Otero, Paula
Paiva, Bruno
van de Donk, Niels
Martin, Thomas
Suvannasankha, Attaya
Madduri, Deepu
Corsale, Christina
Schecter, Jordan
De Braganca, Kevin
Jackson, Carolyn
Varsos, Helen
Deraedt, William
Roccia, Tito
Mistry, Pankaj
Xu, Xiaoying
Li, Katherine
Zudaire, Enrique
Akram, Muhammad
Pacaud, Lida
Avivi, Irit
San-Miguel, Jesus
BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 104 - 105
[5] Cardiovascular Adverse Events After Anti-BCMA CAR-T (Ide-Cel and Cilta-Cel) for Relapsed/ Refractory Multiple Myeloma
Palfi, Stefanie
Koelmeyer, Himara
Alsina, Melissa
Baz, Rachid
Blue, Brandon
Corallo, Salvatore
De Avila, Gabriel
Freeman, Ciara
Grajales-Cruz, Ariel
Harvey, Kristy
Liu, Hien
Nishihori, Taiga
Oliveira, Guilherme
Oswald, Laura
Puglianini, Omar Castaneda
Shain, Kenneth
Wettenstein, Zachary
Jain, Michael
Locke, Frederick
Alomar, Mohammed
Hansen, Doris
Lee, Dae Hyun
CIRCULATION, 2024, 150
[6] Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma
Chekol Abebe, Endeshaw
Yibeltal Shiferaw, Mestet
Tadele Admasu, Fitalew
Asmamaw Dejenie, Tadesse
FRONTIERS IN IMMUNOLOGY, 2022, 13
[7] Updated Results of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)
Usmani, Saad Z.
Berdeja, Jesus G.
Madduri, Deepu
Jakubowiak, Andrzej
Agha, Mounzer
Cohen, Adam D.
Hari, Parameswaran
Yeh, Tzu-Min
Olyslager, Yunsi
Banerjee, Arnob
Jackson, Carolyn C.
Allred, Alicia
Zudaire, Enrique
Deraedt, William
Wu, Xiaoling
Carrasco-Alfonso, Marlene J.
Akram, Muhammad
Lin, Yi
Martin, Thomas
Jagannath, Sundar
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S422 - S423
[8] Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma
Martin, Thomas G.
Madduri, Deepu
Pacaud, Lida
Usmani, Saad Z.
FUTURE ONCOLOGY, 2023, 19 (34) : 2297 - 2311
[9] Single-cell transcriptomic atlas throughout anti-BCMA CAR-T therapy in patients with multiple myeloma
Xia, Yuan
Zhao, Qian
Shen, Xuxing
Jin, Yuanyuan
Wang, Jing
Zhu, Jianfeng
Chen, Lijuan
FRONTIERS IN IMMUNOLOGY, 2023, 14
[10] Efficacy and safety of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma and prior noncellular anti-BCMA therapy: CARTITUDE-2 cohort C
Cohen, Adam
Cohen, Yael
Suvannasankha, Attaya
van de Donk, Niels
San-Miguel, Jesus
De Braganca, Kevin
Jackson, Carolyn
Schecter, Jordan
Vlummens, Philip
Varsos, Helen
Corsale, Christina
Mistry, Pankaj
Song, Qingxuan
Roccia, Tito
Geng, Dong
Zhu, Jieqing
Akram, Muhammad
Mateos, Maria-Victoria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S167 - S168

← 1 2 3 4 5 →